Area of research
Immunology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Ferroptosis and cancer prognosis, Hepatocellular Carcinoma Treatment and Prognosis, Immune cells in cancer, and Liver Disease Diagnosis and Treatment.
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma
Human-correlated genetic models identify precision therapy for liver cancer
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
CXCR2 inhibition enables NASH-HCC immunotherapy
Author Correction: Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
CXCR2 inhibition enables NASH-HCC immunotherapy
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
Corrigendum to ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’ [J Hepatol 75 (2021) 865–878]
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents
Platelet GPIba is a mediator and potential interventional target for NASH and subsequent liver cancer
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma
Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma